A detailed history of Oppenheimer & CO Inc transactions in Tyra Biosciences, Inc. stock. As of the latest transaction made, Oppenheimer & CO Inc holds 82,238 shares of TYRA stock, worth $1.28 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
82,238
Previous 74,033 11.08%
Holding current value
$1.28 Million
Previous $708,000 62.43%
% of portfolio
0.01%
Previous 0.01%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 05, 2025

BUY
$9.59 - $13.99 $78,685 - $114,787
8,205 Added 11.08%
82,238 $1.15 Million
Q2 2025

Jul 31, 2025

SELL
$7.06 - $10.86 $5,450 - $8,383
-772 Reduced 1.03%
74,033 $708,000
Q1 2025

Apr 22, 2025

SELL
$9.3 - $16.73 $5,896 - $10,606
-634 Reduced 0.84%
74,805 $695,000
Q4 2024

Feb 04, 2025

SELL
$13.9 - $28.61 $19,001 - $39,109
-1,367 Reduced 1.78%
75,439 $1.05 Million
Q3 2024

Nov 05, 2024

BUY
$16.7 - $24.36 $105,510 - $153,906
6,318 Added 8.96%
76,806 $1.81 Million
Q2 2024

Aug 07, 2024

BUY
$14.45 - $20.22 $157,678 - $220,640
10,912 Added 18.32%
70,488 $1.13 Million
Q1 2024

May 06, 2024

BUY
$11.61 - $20.0 $691,677 - $1.19 Million
59,576 New
59,576 $977,000

Others Institutions Holding TYRA

About Tyra Biosciences, Inc.


  • Ticker TYRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,973,600
  • Market Cap $652M
  • Description
  • Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The comp...
More about TYRA
Track This Portfolio

Track Oppenheimer & CO Inc Portfolio

Follow Oppenheimer & CO Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Oppenheimer & CO Inc, based on Form 13F filings with the SEC.

News

Stay updated on Oppenheimer & CO Inc with notifications on news.